Loading...
New: AI Readiness Assessment — score your practice in 3 minutes. Take assessment →
Loading...
Clinical Modality publishes custom-built clinical content. A team of clinical and technical researchers produces every release, then Dr. Zalzala clears every clinical claim before publication. Every statement cites primary literature. Every conflict of interest is disclosed in the article footer.
Last reviewed 2026-04-30
Every clinical claim cites primary literature inline (PMID). No 'studies show' hand-waves. No unindexed sources for clinical recommendations. Every citation is verified before publication.
Dr. Sajad Zalzala (50-state licensed MD, AgelessRx co-founder, PEARL trial author) holds final editorial approval through three explicit gates. No clinical claim publishes without his attestation.
Every conflict is disclosed in the article footer and on /about/coi. Dr. Zalzala's AgelessRx affiliation, Isam's Consultanist and EMR Genius / CM Assist affiliations — all named, every time the content touches a topic where they apply.
Every clinical article shows a 'Last reviewed' date. We re-review when a state law, malpractice carrier policy, FDA action, or major guideline changes our recommendation. Articles drift-flagged via search performance are queued for re-review.
Every published article — case briefing, deep sibling, or pillar — passes through three explicit gates. Dr. Zalzala's clinical judgment is the gate at every stage.
Title, learning objectives, target audience, and why-this-matters framing. Built from voice-note conversations with Dr. Zalzala or from cited research the team has assembled. Dr. Zalzala approves before any further work begins.
Five to eight sections with key points, the primary-literature citations they will cite (PMIDs listed), intended length, and illustrative examples. Dr. Zalzala approves the structure before drafting begins — revisions don't pile up at the end.
Drafted in Dr. Zalzala's voice, anchored to the approved sources. Quick Answer block at the top, question-format headings, comparison tables where relevant, FAQ at the bottom. Dr. Zalzala does final review section by section and gives explicit final approval before publication.
Every clinical claim is cleared by Dr. Sajad Zalzala — board-certified physician licensed in all 50 US states and the District of Columbia, co-founder of AgelessRx, senior author on the PEARL rapamycin RCT. Isam Waqar (PMP-certified product engineer, founder of Consultanist) leads the technical and editorial production but does not provide clinical review — he is not a physician.
Every clinical claim cites primary literature inline (PMID — PubMed ID). We do not cite unindexed sources for clinical recommendations. We do not cite preprints for clinical recommendations without explicitly labeling the preprint status. Each cited reference is verified to exist and to support the claim before publication.
A team of clinical and technical researchers produces every release, working from voice-note conversations with Dr. Zalzala, primary literature, and field-tested practice experience. Dr. Zalzala holds final editorial approval at the topic level, the section outline, and the complete draft — no clinical claim publishes without his signature.
Every clinical article publishes a 'Last reviewed' date. We re-review when a state law, malpractice carrier policy, FDA action, or major guideline change makes our prior recommendation stale. Articles flagged with significant rank or CTR drift are queued for re-review automatically. Compliance Bootcamp template materials are refreshed quarterly.
Every conflict of interest is disclosed in the article footer of any affected piece, and on a dedicated /about/coi page. Dr. Zalzala co-founded and works at AgelessRx (a longevity-medicine telehealth company); any Clinical Modality content covering longevity, rapamycin, or AgelessRx-adjacent topics carries this disclosure. Isam Waqar founded Consultanist (the consulting firm that produces Clinical Modality) and is invested in EMR Genius / CM Assist; any content covering those products carries this disclosure.
No. We do not accept sponsorship, paid placement, or affiliate compensation for editorial coverage of any vendor, tool, or company. The single paid offer on the site is the Compliance Bootcamp (a Clinical Modality educational product); there is no third-party advertising or sponsored content. If this changes, the editorial policy will say so explicitly.
If you find an error, use the contact form or write to the Clinical Modality editorial inbox. We correct material errors within 5 business days, append a correction note dated to the article, and re-issue the newsletter if the article was distributed. We do not silently edit clinical claims after publication — every change is visible.
See also conflict-of-interest disclosures and about the hosts.